Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Oct 19;10(10):CD010893.
doi: 10.1002/14651858.CD010893.pub3.

Interventions for reducing inflammation in familial Mediterranean fever

Bin Wu  1 , Ting Xu, Youping Li, Xi Yin
Affiliations
Meta-Analysis

Interventions for reducing inflammation in familial Mediterranean fever

Bin Wu et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Familial Mediterranean fever, a hereditary auto-inflammatory disease, mainly affects ethnic groups living in the Mediterranean region. Early studies reported colchicine as a potential drug for preventing attacks of familial Mediterranean fever. For those people who are colchicine-resistant or intolerant, drugs such as rilonacept, anakinra, canakinumab, etanercept, infliximab, thalidomide and interferon-alpha might be beneficial. This is an updated version of the review.

Objectives: To evaluate the efficacy and safety of interventions for reducing inflammation in people with familial Mediterranean fever.

Search methods: We used detailed search strategies to search the following databases: CENTRAL; MEDLINE; Embase; Chinese Biomedical Literature Database (CBM); China National Knowledge Infrastructure Database (CNKI); Wan Fang; and VIP. In addition, we also searched the clinical trials registries including ClinicalTrials.gov, the International Standard Randomized Controlled Trial Number Register, the WHO International Clinical Trials Registry Platform and the Chinese Clinical Trial Registry, as well as references listed in relevant reports.Date of last search: 21 August 2018.

Selection criteria: Randomized controlled studies (RCTs) of people diagnosed with familial Mediterranean fever, comparing active interventions (including colchicine, anakinra, rilonacept, canakinumab, etanercept, infliximab, thalidomide, interferon-alpha, ImmunoGuard™ (a herbal dietary supplement) and non-steroidal anti-inflammatory drugs) with placebo or no treatment, or comparing active drugs to each other.

Data collection and analysis: The authors independently selected studies, extracted data and assessed risk of bias. We pooled data to present the risk ratio or mean difference with their 95% confidence intervals. We assessed overall evidence quality according to the GRADE approach.

Main results: We included nine RCTs with a total of 249 participants (aged three to 53 years); five were of cross-over and four of parallel design. Six studies used oral colchicine, one used oral ImmunoGuard™ and the remaining two used rilonacept or anakinra as a subcutaneous injection. The duration of each study arm ranged from one to eight months.The three studies of ImmunoGuard™, rilonacept and anakinra were generally well-designed, except for an unclear risk of detection bias in one of these. However, some inadequacy existed in the four older studies on colchicine, which had an unclear risk of selection bias, detection bias and reporting bias, and also a high risk of attrition bias and other potential bias. Neither of the two studies comparing a single to a divided dose of colchicine were adequately blinded, furthermore one study had an unclear risk of selection bias and reporting bias, a high risk of attrition bias and other potential bias.We aimed to report on the number of participants experiencing an attack, the timing of attacks, the prevention of amyloid A amyloidosis, any adverse drug reactions and the response of a number of biochemical markers from the acute phase of an attack, but data were not available for all outcomes across all comparisons.One study (15 participants) reported a significant reduction in the number of people experiencing attacks at three months with 0.6 mg colchicine three times daily (14% versus 100%), risk ratio 0.21 (95% confidence interval 0.05 to 0.95) (low-quality evidence). A further study (22 participants) of 0.5 mg colchicine twice daily showed no significant reduction in the number of participants experiencing attacks at two months (low-quality evidence). A study of rilonacept in individuals who were colchicine-resistant or intolerant (14 participants) also showed no reduction at three months (moderate-quality evidence). Likewise, a study of anakinra given to colchicine-resistant people (25 participants) showed no reduction in the number of participants experiencing an attack at four months (moderate-quality evidence).Three studies reported no significant differences in duration of attacks: one comparing colchicine to placebo (15 participants) (very low-quality evidence); one comparing single-dose colchicine to divided-dose colchicine (90 participants) (moderate-quality evidence); and one comparing rilonacept to placebo (14 participants) (low-quality evidence). Three studies reported no significant differences in the number of days between attacks: two comparing colchicine to placebo (24 participants in total) (very low-quality evidence); and one comparing rilonacept to placebo (14 participants) (low-quality evidence).No study reported on the prevention of amyloid A amyloidosis.One study of colchicine reported loose stools and frequent bowel movements (very low-quality evidence) and a second reported diarrhoea (very low-quality evidence). The rilonacept study reported no significant differences in gastrointestinal symptoms, hypertension, headache, respiratory tract infections, injection site reactions and herpes, compared to placebo (low-quality evidence). The ImmunoGuard study observed no side effects (moderate-quality evidence). The anakinra study reported no significant differences between intervention and placebo, including injection site reaction, headache, presyncope, dyspnea and itching (moderate-quality evidence). When comparing single and divided doses of colchicine, one study reported no difference in adverse events (including anorexia, nausea, diarrhoea, abdominal pain, vomiting and elevated liver enzymes) between groups (moderate-quality evidence) and the second study reported no adverse effects were detected.The rilonacept study reported no significant reduction in acute phase response indicators after three months (low-quality evidence). In the ImmunoGuard™ study, these indicators were not reduced after one month of treatment (moderate-quality evidence). The anakinra study, reported that C-reactive protein was significantly reduced after four months (moderate-quality evidence). One of the single dose versus divided dose colchicine studies reported no significant reduction in acute phase response indicators after eight months (low-quality evidence), while the second study reported no significant reduction in serum amyloid A concentration after six months (moderate-quality evidence).

Authors' conclusions: There were limited RCTs assessing interventions for people with familial Mediterranean fever. Based on the evidence, three times daily colchicine appears to reduce the number of people experiencing attacks, colchicine single dose and divided dose might not be different for children with familial Mediterranean fever and anakinra might reduce C-reactive protein in colchicine-resistant participants; however, only a few RCTs contributed data for analysis. Further RCTs examining active interventions, not only colchicine, are necessary before a comprehensive conclusion regarding the efficacy and safety of interventions for reducing inflammation in familial Mediterranean fever can be drawn.

PubMed Disclaimer

Conflict of interest statement

All authors declare: none known.

Figures

1
1
PRISMA flow diagram of study selection process
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Amaryan 2003 {published data only}
    1. Amaryan G, Astvatsatryan V, Gabrielyan E, Panossian A, Panosyan V, Wikman G. Double‐blind, placebo‐controlled, randomized, pilot clinical trial of ImmunoGuard‐‐a standardized fixed combination of Andrographis paniculata Nees, with Eleutherococcus senticosus Maxim, Schizandra chinensis Bail. and Glycyrrhiza glabra L. extracts in patients with Familial Mediterranean Fever. Phytomedicine 2003;10(4):271‐85. - PubMed
    1. Panossian A, Hambartsumyan M, Panosyan L, Abrahamyan H, Mamikonyan G, Gabrielyan E, et al. Plasma nitric oxide level in familial Mediterranean fever and its modulations by Immuno‐Guard. Nitric Oxide: Biology and Chemistry 2003;9(2):103‐10. - PubMed
Ben‐Zvi 2017 {published data only}
    1. Ben‐Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, et al. Anakinra for colchicine‐resistant familial Mediterranean fever: a randomized, double‐blind, placebo‐controlled trial. Arthritis & Rheumatology 2017;69(4):854‐62. - PubMed
    1. Ben‐Zvi I, Livneh A. Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial. Israel Medical Association Journal 2014;16(5):271‐3. - PubMed
Dinarello 1974 {published data only}
    1. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial Mediterranean fever. A double blind trial. New England Journal of Medicine 1974;291(18):934‐7. - PubMed
    1. Wolff SM, Dinarello CA, Dale DC, Goldfinger SE, Alling DW. Colchicine therapy of familial Mediterranean fever. Transactions of the Association of American Physicians 1974;87:186‐94. - PubMed
Goldstein 1974 {published data only}
    1. Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, double‐blind study. Annals of Internal Medicine 1974;81(6):792‐4. - PubMed
Hashkes 2012 {published data only}
    1. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine‐resistant or ‐intolerant familial Mediterranean fever: a randomized trial. Annals of Internal Medicine 2012;157(8):533‐41. - PubMed
    1. Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Park G, Barron KS, et al. Rilonacept (interleukin‐1 trap) for treatment of colchicine resistant familial Mediterranean fever: a randomized, multicenter double‐blinded, alternating treatment phase II trial. Pediatric Rheumatology 2011;9(Suppl 1):O38.
    1. Hashkes PJ, Spalding SJ, Hajj‐Ali R, Giannini EH, Johnson A, Barron KS, et al. The effect of rilonacept versus placebo on health‐related quality of life in patients with poorly controlled familial Mediterranean fever. BioMed Research International 2014;854842:1‐8. [DOI: 10.1155/2014/854842] - DOI - PMC - PubMed
Kosan 2004 {published data only}
    1. Kosan C, Ozkan B. Once‐daily use of colchicine in children with familial Mediterranean fever. Clinical Pediatrics 2004;43(7):605‐8. - PubMed
Polat 2016 {published data only}
    1. Polat A, Acikel C, Sozeri B, Dursun I, Kasapcopur O, Gulez N, et al. Comparison of the efficacy of once‐ and twice‐daily colchicine dosage in pediatric patients with familial Mediterranean fever‐‐a randomized controlled non‐inferiority trial. Arthritis Research & Therapy 2016;18(85):1‐9. - PMC - PubMed
Wright 1977 {published data only}
    1. Wright DG, Wolff SM, Fauci AS, Alling DW. Efficacy of intermittent colchicine therapy in familial Mediterranean fever. Annals of Internal Medicine 1977;86(2):162‐5. - PubMed
Zemer 1974 {published data only}
    1. Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. New England Journal of Medicine 1974;291(18):932‐4. - PubMed

References to studies excluded from this review

Adler 1998 {published data only}
    1. Adler Y, Finkelstein Y, Guindo J, Rodriguez de la Serna A, Shoenfeld Y, Bayes‐Genis A, et al. Colchicine treatment for recurrent pericarditis. A decade of experience. Circulation 1998;97(21):2183‐5. - PubMed
Alpay 2012 {published data only}
    1. Alpay N, Sumnu A, Calışkan Y, Yazıcı H, Türkmen A, Gül A. Efficacy of anakinra treatment in a patient with colchicine‐resistant familial Mediterranean fever. Rheumatology International 2012;32(10):3277‐9. - PubMed
Anonymous 1977 {published data only}
    1. Anonymous. Colchicine in familial Mediterranean fever. Lancet 1977;1(8022):1140‐1. - PubMed
Anonymous 1983 {published data only}
    1. Anonymous. Colchicine for familial Mediterranean fever. FDA Drug Bulletin 1983;13(1):4. - PubMed
Bakkaloglu 2009 {published data only}
    1. Bakkaloglu SA, Aksu T, Goker B, Unlusoy A, Peru H, Fidan K, et al. Sulphasalazine treatment in protracted familial Mediterranean fever arthritis. European Journal of Pediatrics 2009;168(8):1017‐9. - PubMed
Belkhir 2007 {published data only}
    1. Belkhir R, Moulonguet‐Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T. Treatment of familial Mediterranean fever with anakinra. Annals of Internal Medicine 2007;146(11):825‐6. - PubMed
Ben‐Chetrit 2008 {published data only}
    1. Ben‐Chetrit E, Ozdogan H. Non‐response to colchicine in FMF‐definition, causes and suggested solutions. Clinical and Experimental Rheumatology 2008;26(4 Suppl 50):S49‐51. - PubMed
Brik 2014 {published data only}
    1. Brik R, Butbul‐Aviel Y, Lubin S, Ben Dayan E, Rachmilewitz‐Minei T, Tseng L, et al. Canakinumab for the treatment of children with colchicine‐resistant familial Mediterranean fever: a 6‐month open‐label, single‐arm pilot study. Arthritis & Rheumatology 2014;66(11):3241‐3. - PubMed
Burstein 1997 {published data only}
    1. Burstein R, Seidman DS, Zemer D, Shpilberg O, Arnon R, Epstein Y, et al. Chronic colchicine treatment does not impair glucose tolerance in familial Mediterranean fever patients. European Journal of Clinical Pharmacology 1997;52(1):27‐30. - PubMed
Calligaris 2008 {published data only}
    1. Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine‐resistant familial Mediterranean fever. European Journal of Pediatrics 2008;167(6):695‐6. - PMC - PubMed
Demirkaya 2016 {published data only}
    1. Demirkaya E, Erer B, Ozen S, Ben‐Chetrit E. Efficacy and safety of treatments in familial Mediterranean fever: a systematic review. Rheumatology International 2016;36(3):325‐31. - PubMed
Dinarello 1976 {published data only}
    1. Dinarello CA, Chusid MJ, Fauci AS, Gallin JI, Dale DC, Wolff SM. Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever. Arthritis & Rheumatism 1976;19(3):618‐22. - PubMed
Gattringer 2007 {published data only}
    1. Gattringer R, Lagler H, Gattringer KB, Knapp S, Burgmann H, Winkler S, et al. Anakinra in two adolescent female patients suffering from colchicine‐resistant familial Mediterranean fever: effective but risky. European Journal of Clinical Investigation 2007;37(11):912‐4. - PubMed
Gül 2015 {published data only}
    1. Gül A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine‐resistant familial Mediterranean fever. Arthritis Research & Therapy 2015;17(243):1‐5. - PMC - PubMed
Hashkes 2014 {published data only}
    1. Hashkes P, Butbul Aviel Y, Lubin S, Ben‐Dayan E, Tseng L, Brik R. Long‐term efficacy of canakinumab in childhood colchicine resistant familial Mediterranean Fever. Arthritis & Rheumatism 2014;66(Suppl 11):S108. [Abstract no.: A76] - PubMed
Haviv 2016 {published data only}
    1. Haviv R, Hashkes PJ. Canakinumab investigated for treating familial Mediterranean fever. Expert Opinion on Biological Therapy 2016;16(11):1425‐34. - PubMed
Hoffman 2008 {published data only}
    1. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin‐1 Trap) in patients with cryopyrin‐associated periodic syndromes: results from two sequential placebo‐controlled studies. Arthritis & Rheumatism 2008;58(8):2443‐52. - PubMed
Kuijk 2007 {published data only}
    1. Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ. Effective treatment of a colchicine‐resistant familial Mediterranean fever patient with anakinra. Annals of the Rheumatic Diseases 2007;66(11):1545‐6. - PMC - PubMed
Lidar 2004 {published data only}
    1. Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni Baruch R, et al. Colchicine non‐responsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Seminars in Arthritis and Rheumatism 2004;33(4):273‐82. - PubMed
Mor 2007 {published data only}
    1. Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A. Familial Mediterranean fever successfully treated with etanercept. Journal of Clinical Rheumatology 2007;13(1):38‐40. - PubMed
Moser 2009 {published data only}
    1. Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrology, Dialysis, Transplantation 2009;24(2):676‐8. - PubMed
Ofir 2008 {published data only}
    1. Ofir D, Levy A, Wiznitzer A, Mazor M, Sheiner E. Familial Mediterranean fever during pregnancy: an independent risk factor for preterm delivery. European Journal of Obstetrics, Gynaecology and Reproductive Biology 2008;141(2):115‐8. - PubMed
Ozdogan 2017 {published data only}
    1. Ozdogan H, Ugurlu S. Canakinumab for the treatment of familial Mediterranean fever. Expert Review of Clinical Immunology 2017;13(5):393‐404. - PubMed
Roldan 2008 {published data only}
    1. Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 2008;75(4):504‐5. - PubMed
Sakallioglu 2006 {published data only}
    1. Sakallioglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clinical and Experimental Rheumatology 2006;24(4):435‐7. - PubMed
Sarkissian 2000 {published data only}
    1. Sarkissian A, Papazian M, Sanamyan A, Leumann E. Colchicine in the treatment of renal amyloidosis secondary to familial Mediterranean fever. Nephrology, Dialysis, Transplantation 2000;15(7):1098. - PubMed
Seyahi 2002 {published data only}
    1. Seyahi E, Ozdogan H, Masatlioglu S, Yazici H. Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient. clinical and Experimental Rheumatology 2002;20(4 Suppl 26):S43‐4. - PubMed
Seyahi 2006 {published data only}
    1. Seyahi E, Ozdogan H, Celik S, Ugurlu S, Yazici H. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clinical and Experimental Rheumatology 2006;24(5 Suppl 42):S99‐103. - PubMed
Stankovic Stojanovic 2012 {published data only}
    1. Stankovic Stojanovic K, Delmas Y, Torres PU, Peltier J, Pelle G, Jéru I, et al. Dramatic beneficial effect of interleukin‐1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrology, Dialysis, Transplantation 2012;27(5):1898‐901. - PubMed
Ter Haar 2013 {published data only}
    1. Ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases 2013;72(5):678‐85. - PubMed
Tunca 2004 {published data only}
    1. Tunca M, Akar S, Soyturk M, Kirkali G, Resmi H, Akhunlar H, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double‐blind, placebo‐controlled trial. Clinical and Experimental Rheumatology 2004;22(4 Suppl 24):S37‐S40. - PubMed
Tweezer‐Zaks 2008 {published data only}
    1. Tweezer‐Zaks N, Rabinovich E, Lidar M, Livneh A. Interferon‐alpha as a treatment modality for colchicine‐resistant familial Mediterranean fever. Journal of Rheumatology 2008;35(7):1362‐5. - PubMed
Uguztemur 2017 {published data only}
    1. Uguztemur E, Celik S, Sadri S, Ergun G, Asci E, Velipasalar O, et al. The efficacy of different colchicine doses in treatment of familial Mediterranean fever patients. Annals of Rheumatic Diseases 2017;76(Supplement 2):716.
Yenokyan 2012 {published data only}
    1. Yenokyan G, Armenian HK. Triggers for attacks in familial Mediterranean fever: application of the case‐crossover design. American Journal of Epidemiology 2012;175(10):1054‐61. - PubMed
Zemer 1986 {published data only}
    1. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni, J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. New England Journal of Medicine 1986;314(16):1001‐5. - PubMed
Zemer 1991 {published data only}
    1. Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long‐term colchicine treatment in children with familial Mediterranean fever. Arthritis & Rheumatism 1991;34(8):973‐7. - PubMed

References to studies awaiting assessment

De Benedetti 2018 {published data only}
    1. Benedetti F, Anton J, Gattorno M, Lachmann H, Kone‐Paut I, Ozen S, et al. Efficacy and safety of Canakinumab in patients with periodic fever syndromes (colchicine‐resistant fmf, hids/mkd and traps): results from a phase 3, pivotal, umbrella trial. Pediatric Rheumatology 2017;15(Supplement 1):no pagination.
    1. Benedetti F, Gattorno M, Anton J, Ben‐Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. New England Journal of Medicine 2018;378(20):1908‐19. - PubMed
    1. Benedetti F, Miettunen P, Kallinich T, Horneff G, Brik R, Tomassini A, et al. Genetic phenotypes impacting efficacy and safety of canakinumab in patients with colchicine‐resistant FMF, traps and HIDS/MKD: results from cluster study. Arthritis & Rheumatology 2017;69(S10):no pagination.
    1. Kone‐Paut I, Hofer M, Benseler S, Kuemmerle‐Deschner JB, Jansson A, Rosner I, et al. Improvement of disease activity in patients with colchicine‐resistant FMF, HIDS/MKD and traps assessed by autoinflammatory disease activity index (AIDAI): Results from a randomized phase iii trial. Arthritis & Rheumatology 2017;69(S10):398‐9.
    1. Lachmann H, Simon A, Anton J, Gattorno M, Kone‐Paut I, Ozen S, et al. Effect of canakinumab on health‐related quality of life in patients with periodic fever syndromes. Pediatric Rheumatology. Conference: 23rd Paediatric Rheumatology European Society Congress. 2017; Vol. 15:no pagination.

References to ongoing studies

NCT03446209 {published data only}
    1. NCT03446209. Tocilizumab for the treatment of familial Mediterranean fever. clinicaltrials.gov/ct2/show/NCT03446209 (first received 26 February 2018).

Additional references

Balci 2002
    1. Balci B, Tinaztepe K, Yilmaz E, Guçer S, Ozen S, Topaloğlu R, et al. MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study. Nephrology Dialysis Transplantation 2002;17(11):1921‐3. - PubMed
Baykal 2003
    1. Baykal Y, Saglam K, Yilmaz MI, Taslipinar A, Akinci SB, Inal A. Serum sIL‐2r, IL‐6, IL‐10 and TNF‐alpha level in familial Mediterranean fever patients. Clinical Rheumatology 2003;22(2):99‐101. - PubMed
Ben‐Chetrit 2006
    1. Ben‐Chetrit E, Bergmann S, Sood R. Mechanism of the anti‐inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. Rheumatology (Oxford) 2006;45(3):274‐82. - PubMed
Bilgen 2011
    1. Bilgen SA, Kilic L, Akdogan A, Kiraz S, Kalyoncu U, Karadag O, et al. Effects of anti‐tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. Journal of Clinical Rheumatology 2011;17(7):358‐62. - PubMed
Centola 2000
    1. Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000;95(10):3223‐31. - PubMed
Cerquaglia 2005
    1. Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Current Drug Targets. Inflammation and Allergy 2005;4(1):117‐24. - PubMed
Chae 2009
    1. Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. British Journal of Haematology 2009;146(5):467‐78. - PMC - PubMed
Cronstein 2006
    1. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Research and Therapy 2006;8 Suppl 1:S3. - PMC - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DGonbehalfoftheCSMG, editor(s). Chapter 9: Analysing data and undertaking meta‐analysis. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from cochrane‐handbook.org.
Economides 2003
    1. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler‐Stec EM, Hartnett C, et al. Cytokine traps: multi‐component, high‐affinity blockers of cytokine action. Nature Medicine 2003;9(1):47‐52. - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Endnote X6 2012 [Computer program]
    1. Thomson Reuters. Endnote X6. Version 6.0. San Francisco: Thomson Reuters, 2012.
French FMF Consortium 1997
    1. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nature Genetics 1997;17(1):25‐31. - PubMed
Goldfinger 1972
    1. Goldfinger SE. Colchicine for familial Mediterranean fever. The New England Journal of Medicine 1972;287(25):1302. - PubMed
GRADE 2013
    1. The GRADE Working Group. GRADE Profiler 3.6 for Windows. http://tech.cochrane.org/revman/gradepro 2013.
Heilig 2018
    1. Heilig R, Broz P. Function and mechanism of the pyrin inflammasome. European Journal of Immunology 2018;48(2):230‐8. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011a
    1. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011b
    1. Higgins JPT, Altman DG, Sterne JAC on behalf of the CSMG and the CBMG, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011c
    1. Higgins JPT, Deeks JJ, Altman DG on behalf of the CSMG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Kiraz 1998
    1. Kiraz S, Ertenli I, Arici M, Calgüneri M, Haznedaroglu I, Celik I, et al. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clinical and Experimental Rheumatology 1998;16(6):721‐4. - PubMed
Konstantopoulos 2003
    1. Konstantopoulos K, Kanta A, Deltas C, Atamian V, Mavrogianni D, Tzioufas AG, et al. Familial Mediterranean fever associated pyrin mutations in Greece. Annals of the Rheumatic Diseases 2003;62(5):479‐81. - PMC - PubMed
Koné‐Paut 2011
    1. Koné‐Paut I, Hentgen V, Touitou I. Current data on familial Mediterranean fever. Joint Bone Spine 2011;78(2):111‐4. - PubMed
La Regina 2003
    1. Regina M, Nucera G, Diaco M, Procopio A, Gasbarrini G, Notarnicola C, et al. Familial Mediterranean fever is no longer a rare disease in Italy. European Journal of Human Genetics 2003;11(1):50‐6. - PubMed
Lidar 2006
    1. Lidar M, Yaqubov M, Zaks N, Ben‐Horin S, Langevitz P, Livneh A. The prodrome: a prominent yet overlooked pre‐attack manifestation of familial Mediterranean fever. Journal of Rheumatology 2006;33(6):1089‐92. - PubMed
Livneh 1997
    1. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis and Rheumatism 1997;40(10):1879‐85. - PubMed
Livneh 2000
    1. Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Baillière's Best Practice & Research. Clinical Rheumatology 2010;14(3):477‐98. - PubMed
Livneh 2006
    1. Livneh A. Amyloidosis of familial Mediterranean fever (FMF)‐‐insights to FMF phenotype II. Harefuah 2006;145(10):743‐5, 782. - PubMed
Mansfield 2001
    1. Mansfield E, Chae JJ, Komarow HD, Brotz TM, Frucht DM, Aksentijevich I, et al. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood 2001;98(3):851‐9. - PubMed
Melikoğlu 2000
    1. Melikoğlu M, Ozdoğan H, Korkmaz C, Kasapçopur O, Arisoy N, Akkuş S, et al. A survey of phenotype II in familial Mediterranean fever. Annals of the Rheumatic Diseases 2000;59(11):910‐3. - PMC - PubMed
Migita 2012
    1. Migita K, Uehara R, Nakamura Y, Yasunami M, Tsuchiya‐Suzuki A, Yazaki M, et al. Familial Mediterranean fever in Japan. Medicine (Baltimore) 2012;91(6):337‐43. - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. Journal of Clinical Epidemiology 2009;62:1006‐12. - PubMed
Moher 2012
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. International Journal of Surgery 2012;10(1):28‐55. - PubMed
Ozen 2011
    1. Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti‐interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. Journal of Rheumatology 2011;38(3):516‐8. - PubMed
Ozen 2016
    1. Ozen S, Demirkaya E, Erer B, Livneh A, Ben‐Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases 2016;75(4):644‐51. - PubMed
Ozen 2017
    1. Ozen S, Batu ED, Demir S. Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management. Frontiers in Immunology 2017;8(253):1‐11. - PMC - PubMed
Park 2016
    1. Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nature Immunology 2016;17(8):914‐21. - PMC - PubMed
Review Manager 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sampaio 1991
    1. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. Journal of Experimental Medicine 1991;173(3):699‐703. - PMC - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Shohat 2011
    1. Shohat M, Halpern GJ. Familial Mediterranean fever‐‐a review. Genetics in Medicine 2011;13(6):487‐98. - PubMed
Soriano 2012
    1. Soriano A, Manna R. Familial Mediterranean fever: new phenotypes. Autoimmunity Reviews 2012;12(1):31‐7. - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Moher D on behalf of the CBMG, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Terkeltaub 2009
    1. Terkeltaub RA. Colchicine update: 2008. Seminars in Arthritis and Rheumatism 2009;38(6):411‐9. - PubMed
Terkeltaub 2013
    1. Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Research and Therapy 2013;15(1):R15. - PMC - PubMed
The International FMF Consortium 1997
    1. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997;90(4):797‐807. - PubMed
WHO 2013
    1. WHO. 19th Expert Committee: Expert reviews. www.who.int/selection_medicines/committees/expert/19/reviews/en/index.html (accessed 13 June 2013).
Xu 2014
    1. Xu H, Yang J, Gao W, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 2014;513(7517):237‐41. - PubMed
Yalçinkaya 2009
    1. Yalçinkaya F, Ozen S, Ozçakar ZB, Aktay N, Cakar N, Düzova A, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009;48(4):395‐8. - PubMed
Özçakar 2012
    1. Özçakar ZB, Yüksel S, Ekim M, Yalçınkaya F. Infliximab therapy for familial Mediterranean fever‐related amyloidosis: case series with long term follow‐up. Clinical Rheumatology 2012;31(8):1267‐71. - PubMed

References to other published versions of this review

Wu 2015
    1. Wu B, Xu T, Li Y, Yin X. Interventions for reducing inflammation in familial Mediterranean fever. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD010893.pub2] - DOI - PubMed

MeSH terms